Gilead Sciences, Inc. (GILD) Shares Bought by State of Wisconsin Investment Board

State of Wisconsin Investment Board grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,031,340 shares of the biopharmaceutical company’s stock after acquiring an additional 264,180 shares during the period. State of Wisconsin Investment Board owned about 0.16% of Gilead Sciences worth $143,778,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the company. Denver Investment Advisors LLC raised its stake in shares of Gilead Sciences by 23.7% in the 2nd quarter. Denver Investment Advisors LLC now owns 7,572 shares of the biopharmaceutical company’s stock valued at $536,000 after acquiring an additional 1,449 shares during the period. WASHINGTON TRUST Co raised its stake in shares of Gilead Sciences by 4.9% in the 2nd quarter. WASHINGTON TRUST Co now owns 4,387 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 203 shares during the period. Morningstar Investment Services LLC raised its stake in shares of Gilead Sciences by 23.0% in the 2nd quarter. Morningstar Investment Services LLC now owns 68,338 shares of the biopharmaceutical company’s stock valued at $4,837,000 after acquiring an additional 12,774 shares during the period. Dupont Capital Management Corp raised its stake in shares of Gilead Sciences by 11.1% in the 2nd quarter. Dupont Capital Management Corp now owns 240,076 shares of the biopharmaceutical company’s stock valued at $16,993,000 after acquiring an additional 23,964 shares during the period. Finally, Shufro Rose & Co. LLC raised its stake in shares of Gilead Sciences by 8.9% in the 2nd quarter. Shufro Rose & Co. LLC now owns 4,900 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 400 shares during the period. 73.97% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently issued reports on GILD. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Barclays PLC reaffirmed an “overweight” rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday, October 11th. Finally, Leerink Swann reaffirmed a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 25th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.80.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 80.24 on Wednesday. The stock has a market cap of $104.79 billion, a P/E ratio of 8.72 and a beta of 1.14. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm’s 50-day moving average is $82.48 and its 200-day moving average is $72.25.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the business earned $3.08 earnings per share. The company’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.73 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock worth $39,298,919. Company insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by State of Wisconsin Investment Board” was first published by The Ledger Gazette and is owned by of The Led

Several other institutional investors also recently added to or reduced their stakes in the company. Denver Investment Advisors LLC raised its stake in shares of Gilead Sciences by 23.7% in the 2nd quarter. Denver Investment Advisors LLC now owns 7,572 shares of the biopharmaceutical company’s stock valued at $536,000 after acquiring an additional 1,449 shares during the period. WASHINGTON TRUST Co raised its stake in shares of Gilead Sciences by 4.9% in the 2nd quarter. WASHINGTON TRUST Co now owns 4,387 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 203 shares during the period. Morningstar Investment Services LLC raised its stake in shares of Gilead Sciences by 23.0% in the 2nd quarter. Morningstar Investment Services LLC now owns 68,338 shares of the biopharmaceutical company’s stock valued at $4,837,000 after acquiring an additional 12,774 shares during the period. Dupont Capital Management Corp raised its stake in shares of Gilead Sciences by 11.1% in the 2nd quarter. Dupont Capital Management Corp now owns 240,076 shares of the biopharmaceutical company’s stock valued at $16,993,000 after acquiring an additional 23,964 shares during the period. Finally, Shufro Rose & Co. LLC raised its stake in shares of Gilead Sciences by 8.9% in the 2nd quarter. Shufro Rose & Co. LLC now owns 4,900 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 400 shares during the period. 73.97% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently issued reports on GILD. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Barclays PLC reaffirmed an “overweight” rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday, October 11th. Finally, Leerink Swann reaffirmed a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 25th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.80.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 80.24 on Wednesday. The stock has a market cap of $104.79 billion, a P/E ratio of 8.72 and a beta of 1.14. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm’s 50-day moving average is $82.48 and its 200-day moving average is $72.25.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the business earned $3.08 earnings per share. The company’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.73 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock worth $39,298,919. Company insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by State of Wisconsin Investment Board” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/18/gilead-sciences-inc-gild-shares-bought-by-state-of-wisconsin-investment-board.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply